The effect of the mode of administration on the hypolipidaemic activity of niacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats

Journal of Pharmacy and Pharmacology

Volumn 50, Issue 11, 1998, Pages 1233-1239

  Lomnicky, Yossef ^a   Friedman, Michael ^a   Luria, Myron H ^b   Raz, Itamar ^b   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL; TYLOXAPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTINUOUS INFUSION; CONTROLLED STUDY; DUODENUM; HYPERLIPIDEMIA; INTRAGASTRIC DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; SUSTAINED RELEASE PREPARATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031788796     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1998.tb03339.x     Document Type: Article

References (26)

1. Altschul, R., Hoffer, A., Stephen, J. D. (1955) Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys. 54: 558-559
2. Brown, B. G., Bardsley, J., Poulin, D., Hillger, L. A., Dowdy, A., Maher, V. M. G., Zhao, X., Albers, J. J., Knopp, R. H. (1997) Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol < 100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am. J. Cardiol. 80: 111-115
3. Castaneda-Hernandez, G., Caille, G., Du Souich, P. (1994) Influence of drug formulation on drug concentration-effect relationships. Clin. Pharmacokinet. 26: 135-143
4. Dalton, T. A., Berry, R. S. (1992) Hepatotoxicity associated with sustained-release niacin. Am. J. Med. 93: 102-104
5. DiPalma, J. R., Thayer, W. S. (1991) Use of niacin as a drug. Annu. Rev. Nutr. 11: 169-187
6. Drood, J. M., Zimetbaum, P. J., Frishman, W. H. (1991) Nicotinic acid for the treatment of hyperlipoproteinemia. J. Clin. Pharmacol. 31: 641-650
7. Etchason, J. A., Miller, T. D., Squires, R. W., Allison, T. G., Gau, G. T., Marttila, J. K., Kottke, B. A. (1991) Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin. Proc. 66: 23-28
8. Grundy, S. M., Mock, H. Y. I., Zech, L., Herman, M. (1981) Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J. Lipid Res. 22: 24-36
9. Henkin, Y., Oberman, A., Hurst, D. C. (1991) Niacin revised: clinical observations on an important but underutilized drug. Am. J. Med. 91: 239-246
10. Keenan, J. M., Fontaine, P. L., Wenz, J. B., Myers, S., Huang, Z., Rispin, C. M. (1991) Niacin revised: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch. Intern. Med. 151: 1424-1432
11. Knopp, R. H., Ginsberg, J., Albers, J. J., Hoff, C., Oglivie, J. T., Warnick, G. R., Burrows, E., Retziaff, B., Poole, M. (1985) Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34: 642-650
12. Krishnamurthy, A., Thapar, G. S. (1991) Effect of bezafibrate and nicotinic acid on triton induced hyperlipidemias in CFY rats. Indian J. Med. Res. 94: 395-398
13. LaRosa, J. C. (1982) The mechanism of action of lipid-lowering drugs. J. Vasc. Dis. 9: 562-576
14. Lavie, C. J., Mailander, L., Milani, R. V. (1992) Marked benefit with sustained-release niacin therapy in patients "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am. J. Cardiol. 69: 1083-1085
15. Lawrence, S. T. (1993) Transient focal hepatic defects related to sustained-release niacin. J. Clin. Gastroenterol. 16: 234-236
16. Luria, M. H. (1988) Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch. Intern. Med. 148: 2493-2495
17. Luria, M. H., Sapoznikov, D. (1993) Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience. Postgrad. Med. J. 69: 296-299
18. Mckenney, J. M., Proctor, J. D., Harris, S., Chinchili, V. M. (1994) A comparison of the efficacy and toxic effects of sustained vs immediate-release niacin in hypercholesterolemic patients. J. Am. Med. Assn. 271: 672-677
19. Ohata, I., Sakamoto, N., Nitatori, R., Maeno, H. (1983) Aminophenyl ether compound (YM-95831), a new hypolipidemic agent with a high density lipoprotein elevating activity in rats. Drug Res. 33: 237-241
20. Olivier, P., Plancke, M. O., Marzin, D., Clavey, V., Sauzieres, J., Fruchart, J. C. (1988) Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. Atherosclerosis 70: 107-114
21. Rader, J. I., Calvert, R. J., Hathcock, J. N. (1992) Hepatic toxicity of unmodified and time-release preparations of niacin. Am. J. Med. 92: 77-81
22. Shurr, P. E., Schultz, J. R., Parkinson, T. M. (1971) Triton-induced hyperlipidemia in rat model for screening hypolipidemic drugs. Lipids 7: 68-74
23. Sirtori, C. R., Gomarasca, P., D'atri, G., Cerruti, S., Tronconi, G., Scolastico, C. (1978) Pharmacological profile of BR-931, a new hypolipidemic agent that increases high-density lipoproteins. Atherosclerosis 30: 45-56
24. Takeuchi, N., Murase, M., Nomura, Y., Takase, H., Uchida, K. (1987) Effects of triton WR-1339 and orotic acid on lipid metabolism in rats. Lipids 22: 566-571
25. +2 precipitation procedure for quantitation of high-density lipoprotein cholesterol. In: Cooper, G. R. (ed.) Selected Methods of Clinical Chemistry. American Association for Clinical Chemistry, Washington DC, 10: 91-99
26. Young, D. S., Pestaner, L. C., Gibberman, V. (1975) Effects of drugs on clinical chemistry tests. Clin. Chem. 21 (Special issue)